

Paweł, Rogala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/966590/publications.pdf>

Version: 2024-02-01

10
papers

66
citations

1684188

5
h-index

1588992

8
g-index

10
all docs

10
docs citations

10
times ranked

94
citing authors

#	ARTICLE	IF	CITATIONS
1	BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. <i>Melanoma Research</i> , 2020, 30, 465-471.	1.2	14
2	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	2.1	12
3	A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma. <i>Tumori</i> , 2020, 106, NP9-NP13.	1.1	8
4	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1949-1958.	4.2	7
5	First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland. <i>Immunotherapy</i> , 2021, 13, 297-307.	2.0	6
6	Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2239.	2.4	6
7	Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma. <i>Cancers</i> , 2022, 14, 110.	3.7	5
8	Treatment of Locally Advanced Merkel Cell Carcinoma—A Multi-Center Study. <i>Cancers</i> , 2022, 14, 422.	3.7	3
9	The Use of ctDNA for BRAF Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma. <i>Cancers</i> , 2022, 14, 777.	3.7	3
10	Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients. <i>Cancers</i> , 2022, 14, 2123.	3.7	2